Evidence builds for non-IPF ILD therapies

How do you treat a patient who doesn’t quite fit the criteria for any ILD diagnostic group? With difficulty. Professor Toby Maher, head of the Fibrosis Research Group at the National Heart and Lung Institute at London’s Imperial College, told the ERS Congress that as many as 10-15% of ILD patients were unclassifiable and there ...